Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C9H19ClN3O5P
CAS Number:
Molecular Weight:
315.69
UNSPSC Code:
12352200
PubChem Substance ID:
MDL number:
InChI
1S/C9H19ClN3O5P/c1-4-17-19(16,18-5-2)8(3)11-9(14)13(12-15)7-6-10/h8H,4-7H2,1-3H3,(H,11,14)
SMILES string
CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O
InChI key
YAKWPXVTIGTRJH-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
storage condition
protect from light
color
light yellow
solubility
H2O: ≥1 mg/mL
originator
Servier
storage temp.
2-8°C
Biochem/physiol Actions
Fotemustine is a third generation nitrosourea, chloroethylating agent used in the treatment of glioma and malignant melanoma.
Features and Benefits
This compound is a featured product for Apoptosis research. Click here to discover more featured Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Servier. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Silvia Mangiacavalli et al.
American journal of hematology, 88(2), 102-106 (2012-12-12)
Since multiple myeloma (MM) is still not-curable, the management of relapse remains challenging. Given the known efficacy of alkylating agents in MM, we conducted a phase I/II study to test a new three drug combination in which Fotemustine (Muphoran), an
Ipilimumab with fotemustine in metastatic melanoma.
Claus Garbe
The Lancet. Oncology, 13(9), 851-852 (2012-08-17)
Anna Maria Di Giacomo et al.
The Lancet. Oncology, 13(9), 879-886 (2012-08-17)
Ipilimumab improves survival of patients with metastatic melanoma, many of whom develop brain metastases. Chemotherapy-induced release of tumour antigens might amplify ipilimumab's antitumour activity. We aimed to investigate the efficacy and safety of ipilimumab plus fotemustine in patients with metastatic
Xavier Durando et al.
Bulletin du cancer, 100(1), 23-28 (2012-08-15)
Brain metastases affect 37% of patients suffering from metastatic melanoma, and their prognosis remains poor, with an overall survival lower than six months. At the moment, there is no standard therapeutic strategy for management of melanoma brain metastases. In some
M Santoni et al.
Anticancer research, 32(3), 1099-1101 (2012-03-09)
Alkylating agents, such as temozolomide (TMZ) and fotemustine (FTM) are widely used in recurrent glioblastoma (GBM) regimes. Several strategies have been proposed to prevent resistance to these agents, by combining or sequencing them. We report the results of a pilot
Articles
Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.
Apoptosis regulation involves multiple pathways and molecules for cellular homeostasis.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service